Remission of Intermediate Uveitis: Incidence and Predictive Factors.
Publication/Presentation Date
4-1-2016
Abstract
PURPOSE: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission.
DESIGN: Retrospective cohort study.
METHODS: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis.
RESULTS: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4-10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42-4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] =3.82; 95% CI, 1.91-7.63), age ≥45 years (HR [vs age < 45 years] = 1.79; 95% CI, 1.03-3.11), female sex (HR = 1.61; 95% CI, 1.04-2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23-6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with differential incidence.
CONCLUSIONS: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission.
Volume
164
First Page
110
Last Page
117
ISSN
1879-1891
Published In/Presented At
Kempen, J. H., Gewaily, D. Y., Newcomb, C. W., Liesegang, T. L., Kaçmaz, R. O., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Sen, H. N., Suhler, E. B., Thorne, J. E., Foster, C. S., Jabs, D. A., Payal, A., Fitzgerald, T. D., & Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group (2016). Remission of Intermediate Uveitis: Incidence and Predictive Factors. American journal of ophthalmology, 164, 110–7.e2. https://doi.org/10.1016/j.ajo.2015.12.034
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
26772874
Department(s)
Administration and Leadership
Document Type
Article